NCT05895110已完成不适用
To Evaluate the Immunogenicity and Safety of Sequentially Enhanced Recombinant Novel Coronavirus Vaccine (CHO Cells) in Patients Aged 3-17 Years After Completion of Two Doses of Novel Coronavirus Inactivated Vaccine
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- SARS-COV-2 neutralizing antibody
研究概览
简要总结
An open experimental design was used in this study, and 240 subjects were planned to be enrolled. To evaluate the immunogenicity and safety of recombinant Novel Coronavirus vaccine (CHO cells) after sequential intensification in populations vaccinated with two doses of marketed Novel Coronavirus inactivated vaccine.
详细描述
One dose of recombinant novel coronavirus vaccine (CHO cell) for test was injected into the upper arm deltoid muscle muscle of the subject
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects aged 3 to 17 years who can provide vaccination information proving that they have received two doses of commercially available Novel Coronavirus inactivated vaccine in the last 6-9 months;
- •The subject voluntarily agrees to participate in the study (and/or the subject's legal guardian voluntarily agrees to allow the child to participate in the study), and the guardian and the subject (aged 8-17) sign the informed consent, and can provide valid identification; Understand and comply with test protocol requirements;
- •Armpit temperature < 37.3℃ (> 14 years old), armpit temperature < 37.5℃ (≤14 years old);
- •Female subjects of reproductive age agree to use effective contraceptive measures from the beginning to the end of the study.
排除标准
- •History of confirmed or asymptomatic coronavirus infection or positive nucleic acid test of novel Coronavirus infection;
- •SARS virus disease history or SARS-COV-2 history;
- •Have taken antipyretics or painkillers within 24 hours before vaccination;
- •Have a history of severe allergy to any component of the test vaccine, including aluminum preparation, such as anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), dyspnea, angiopantic edema, etc.;
- •Persons suffering from the following diseases:
- •In the past 7 days, have suffered from digestive diseases (such as diarrhea, abdominal pain, vomiting, etc.);
- •congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;
- •have thrombocytopenia, any coagulation dysfunction or receive anticoagulant treatment, etc.;
- •Neurological disorders or neurodysplasia (e.g., migraines, epilepsy, stroke, seizures in the last three years, encephalopathy, focal neurological deficits, Guillain-Barre syndrome, encephalomyelitis or transverse myelitis); History of mental illness or family history;
- •History of congenital or acquired immune deficiency or autoimmune disease or treatment with immunomodulators within 6 months, such as immunosuppressive doses of glucocorticoids (dose reference: equivalent to prednisone 20mg/ day, over a week); Or monoclonal antibodies; Or thymosin; Or interferon; However, topical use (such as ointments, eye drops, inhalants or nasal sprays) is allowed;
- •Known to have been diagnosed with an infectious disease, such as active tuberculosis, viral hepatitis or treponema pallidum;
- •Subunit vaccine and inactivated vaccine should be administered within 14 days before experimental vaccine, and live attenuated vaccine should be administered within 30 days before experimental vaccine;
- •Have received blood or blood-related products, including immunoglobulin, within 3 months prior to the trial vaccine; Or planned for use during the study period;
- •People aged 3-17 years who have participated in or are participating in other COVID-19 related clinical trials or have received other COVID-19 vaccines, except those who have completed two doses of marketed Novel Coronavirus inactivated vaccine within 6-9 months;
- •Pregnant (including positive urine pregnancy), or breast-feeding; The Investigator believes that the subject has any disease or condition that may place the subject at unacceptable risk; Subjects cannot meet the requirements of the program; Conditions that interfere with the assessment of vaccine response.
结局指标
主要结局
SARS-COV-2 neutralizing antibody
时间窗: 14 days and 6 months after inoculation
Titers of SARS-COV-2 neutralizing Antibody at 14 days and 6 months after vaccination of recombinant Novel Coronavirus vaccine (CHO cells) (GMT)
次要结局
- SARS-COV-2 neutralizing antibody(14 days and 6 months after inoculation)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) VaccineInfluenza InfectionNCT01201902Green Cross Corporation592
进行中（未招募）
不适用
Study to evaluate the immunogenicity, safety, and reactogenicity of TWINRIX ADULT containing 720 ELISA units of hepatitis A antigen and 20 µg of hepatitis B surface antigen, administered following a two-dose (0, 6 months) schedule in healthy children between the ages of 1 and 11 years.EUCTR2015-001516-35-Outside-EU/EEAGlaxoSmithKline Biologicals178
已完成
3 期
Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South AfricaMeningococcal ImmunisationHealthy VolunteersNCT05794230Sanofi Pasteur, a Sanofi Company1,528
进行中（未招募）
1 期
A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and AboveCOVID-19NCT05365724China National Biotec Group Company Limited280
尚未招募
早期 1 期
A Clinical Study on LM103 Injection for the Treatment of Advanced Solid TumorsSolid TumorNCT05971589Suzhou BlueHorse Therapeutics Co., Ltd.5